Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | April 2011 |
| End Date: | June 2013 |
| Contact: | Pfizer CT.gov Call Center |
| Phone: | 1-800-718-1021 |
Subject And Investigator-Blinded, Sponsor-Open, Randomized, Single-Dose, Placebo-Controlled, 2-Way, 4-Period Crossover Study To Assess Effects Of PF-02545920 On Ketamine-Induced Aberrant Prefrontal Response To Associative Learning In Healthy Subjects
To evaluate whether PF-02545920 reduces the effects of ketamine on brain activation during
causal learning as measured by fMRI compared to placebo in healthy human subjects, and to
evaluate whether behavioral measures of abnormal causal learning under ketamine are reduced
by treatment with PF 02545920.
Inclusion Criteria:
- Healthy male and/or female subjects between the ages of 21 and 45 years, inclusive.
Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110
lbs). (Healthy is defined as no clinically relevant abnormalities identified by a
detailed medical history, full physical examination, including blood pressure and
pulse rate measurement, 12 lead ECG and clinical laboratory tests).
- Right handed as determined by handedness questionnaire.
- Able to read and write English as a primary language.
Exclusion Criteria:
- Female subjects who are pregnant or breastfeeding.
- Any evidence of significant psychosis-like symptoms.
- Known sensitivity to ketamine.
We found this trial at
1
site
Click here to add this to my saved trials
